---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-390951"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2026-09-14T23:12:37+00:00"
generated_at: "2026-09-15T10:05:12.737298+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences prices $400M offering of common stock and pre-funded warrants

## Summary
- 9,079,000 shares priced at $22.03; pre-funded warrants for 9,078,529 shares at $22.029.
- Gross proceeds expected ~$400.0M; closing expected September 15, 2026.
- Net proceeds to advance dabogratinib in LG-UTUC, IR NMIBC, and achondroplasia programs.
- Offering led by RA Capital; Jefferies, Guggenheim, Cantor, Barclays, William Blair as book-runners.
- Warrants exercisable at $0.001; beneficial ownership limits selectable up to 19.99%.

## SEC filing metadata
- accession: 0001193125-26-390951
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2026-09-14T23:12:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/0001193125-26-390951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/d102025d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-390951
- JSON: https://secwatch.observer/filing/0001193125-26-390951.json
- Plain text: https://secwatch.observer/filing/0001193125-26-390951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.